Societe Generale downgraded Merck to Sell from Hold with a $104 price target. The firm notes its estimates are “well below consensus” and thinks the valuation isn’t sufficiently discounting the Keytruda patent expiry, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Gilead, Merck announce Phase 2 data on islatravir-lenacapavir combination
- iTeos Therapeutics appoints DeSimone to board of directors
- Merck downgraded to Buy from Conviction Buy at Goldman Sachs
- Merck receives positive EU CHMP opinion for KEYTRUDA
- NY AG James urges stricter warnings for Merck’s Singulair
